Skip to main content

Association of Race and Ethnicity With High-Potency P2Y12 Inhibitors Prescription Among Patients With Acute MI Undergoing PCI: An Analysis From the CathPCI Registry.

Publication ,  Journal Article
Mansoor, H; Young, R; Kaltenbach, LA; Wojdyla, DM; Shah, B; Gilchrist, IC; Rymer, JA; Elgendy, IY
Published in: Circ Cardiovasc Interv
January 2, 2026

BACKGROUND: Racial and ethnic disparities exist in postacute myocardial infarction (AMI) care. High-potency P2Y12 inhibitors use among patients with AMI who undergo percutaneous coronary intervention (PCI) carries a class I indication in the guidelines. This study aims to examine racial and ethnic differences in high-potency P2Y12 inhibitor prescription on discharge among patients with AMI undergoing PCI. METHODS: Using data from the NCDR Cath PCI registry, we identified consecutive patients with AMI who underwent PCI from April 2018 to June 2023. Likelihood of high-potency P2Y12 inhibitor prescription on discharge was assessed using logistic regression models adjusted for social deprivation index and other patient- and procedure-related variables. RESULTS: Among 1 662 387 patients hospitalized with AMI and who underwent PCI, 165 579 (9.9%) were Black, 58 595 (3.5%) were Asian, and 1 302 576 (78.3%) were of White race, while 135 637 (8.1%) were of Hispanic ethnicity. At discharge 876 078 (52.7%) were prescribed a high-potency P2Y12 inhibitor. Compared with White patients, Black patients were less likely (adjusted odds ratio, 0.93 [95% CI, 0.92-0.94]), while Asians were more likely (adjusted odds ratio, 1.08 [1.07-1.10]) to have a high-potency P2Y12 inhibitor discharge prescription. Compared with non-Hispanics, Hispanic patients were less likely to have a high-potency P2Y12 inhibitor discharge prescription (adjusted odds ratio, 0.95 [95% CI, 0.93-0.96). CONCLUSIONS: In a contemporary national registry of hospitalized patients with AMI who underwent PCI, Black and Hispanic patients were less likely to be discharged on a high-potency P2Y12 inhibitor irrespective of socioeconomic status. These findings highlight an opportunity to achieve equity in guideline-directed AMI pharmacotherapies to improve outcomes.

Duke Scholars

Published In

Circ Cardiovasc Interv

DOI

EISSN

1941-7632

Publication Date

January 2, 2026

Start / End Page

e015600

Location

United States

Related Subject Headings

  • Cardiovascular System & Hematology
  • 3201 Cardiovascular medicine and haematology
  • 1117 Public Health and Health Services
  • 1103 Clinical Sciences
  • 1102 Cardiorespiratory Medicine and Haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Mansoor, H., Young, R., Kaltenbach, L. A., Wojdyla, D. M., Shah, B., Gilchrist, I. C., … Elgendy, I. Y. (2026). Association of Race and Ethnicity With High-Potency P2Y12 Inhibitors Prescription Among Patients With Acute MI Undergoing PCI: An Analysis From the CathPCI Registry. Circ Cardiovasc Interv, e015600. https://doi.org/10.1161/CIRCINTERVENTIONS.125.015600
Mansoor, Hend, Rebecca Young, Lisa A. Kaltenbach, Daniel M. Wojdyla, Binita Shah, Ian C. Gilchrist, Jennifer A. Rymer, and Islam Y. Elgendy. “Association of Race and Ethnicity With High-Potency P2Y12 Inhibitors Prescription Among Patients With Acute MI Undergoing PCI: An Analysis From the CathPCI Registry.Circ Cardiovasc Interv, January 2, 2026, e015600. https://doi.org/10.1161/CIRCINTERVENTIONS.125.015600.
Mansoor H, Young R, Kaltenbach LA, Wojdyla DM, Shah B, Gilchrist IC, et al. Association of Race and Ethnicity With High-Potency P2Y12 Inhibitors Prescription Among Patients With Acute MI Undergoing PCI: An Analysis From the CathPCI Registry. Circ Cardiovasc Interv. 2026 Jan 2;e015600.
Mansoor, Hend, et al. “Association of Race and Ethnicity With High-Potency P2Y12 Inhibitors Prescription Among Patients With Acute MI Undergoing PCI: An Analysis From the CathPCI Registry.Circ Cardiovasc Interv, Jan. 2026, p. e015600. Pubmed, doi:10.1161/CIRCINTERVENTIONS.125.015600.
Mansoor H, Young R, Kaltenbach LA, Wojdyla DM, Shah B, Gilchrist IC, Rymer JA, Elgendy IY. Association of Race and Ethnicity With High-Potency P2Y12 Inhibitors Prescription Among Patients With Acute MI Undergoing PCI: An Analysis From the CathPCI Registry. Circ Cardiovasc Interv. 2026 Jan 2;e015600.

Published In

Circ Cardiovasc Interv

DOI

EISSN

1941-7632

Publication Date

January 2, 2026

Start / End Page

e015600

Location

United States

Related Subject Headings

  • Cardiovascular System & Hematology
  • 3201 Cardiovascular medicine and haematology
  • 1117 Public Health and Health Services
  • 1103 Clinical Sciences
  • 1102 Cardiorespiratory Medicine and Haematology